- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01924806
A Pilot Study of the WoundWand™ Debridement Device on Infection Prevention (WoundWand)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Montpellier, France
- Hôpital Lapeyronie
-
-
-
-
-
Manchester, United Kingdom, M13 0JE
- Manchester Diabetes Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Subjects who meet the following criteria may be included in the clinical investigation, if they present with ALL of the following:
- Subject is able to understand the evaluation and willing to consent and comply with all post-debridement visits and procedures
- Age 18 years and older. Subjects may be of either sex and of any race or skin type
Subjects fulfilling any one or all of the following criteria:
- chronic wound(s) below the level of the knee, defined by delayed healing or cellular senescence
- acute wound(s) as a result of a surgical procedure, laceration, abrasion or trauma
- diabetic foot ulcer(s)
- subjects with venous leg ulcers below the knee on the leg or foot with one or more documented failure of maximal medical therapy for their study wound >30 days such as compression bandages (low elasticity, elastic, multilayered, elastic and non elastic compression)
Subjects with the following lab results within 30 days of treatment:
- serum albumin level >20g/L
- clinically non significant results of liver function test (LFTs), serum glucose and complete blood count (CBC) with differential
- Subjects with a Braden Score ≥13-14 (Moderate Risk)
- Subjects with adequate arterial blood flow [Ankle-Brachial Index (ABI) >0.75]
Exclusion Criteria
Subjects will be excluded from the clinical investigation, if they present with ANY of the following:
- Subjects that have tunneling wounds
Subject presents with an active infection in the study wound, as defined by purulence and:
Fever and leukocytosis
OR any TWO of the following:
- Malodor, pain or tenderness, warmth, erythema, induration, swelling, lymphangitis
- Infected bone diagnosed by imaging modality (e.g., Magnetic Resonance Imaging (MRI) and/or radiographic images)
- Subjects whose study wound does not require debridement
- Cardiac pacemaker or other electronic implant(s)
- Subjects with irradiate, burn or ischaemic wounds or history of keloids
- Subjects with vasculitis, non-reconstructive peripheral vascular disease, pyoderma gangrenosum, renal failure or lymphoedema
- Subjects with uncontrolled bleeding disorder (PT/PTT) and coagulopathy (including those with hemophilia)
Subjects taking treatment with any of the following:
- Systemic corticosteroids
- Immunosuppressive agent(s)
- Chemotherapy or Radiation therapy
- Subjects deemed to require biologic dressing/ skin substitute
- Terminally ill subjects
- Subjects that have an immunodeficiency disorder that interferes with wound healing, including Acquired Immunodeficiency Syndrome (AIDS) or know to be infected with Human Immunodeficiency Virus (HIV)
- Subjects that have chronic skin conditions such as psoriasis, etc.
- Subjects that reside in a nursing home
- Subject is physically or mentally compromised (e.g., currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.) to the extent that the Investigator judges the subject to be unable or unlikely to remain compliant
- Subject is pregnant and/or intending to become pregnant during this clinical investigation period
- Subject has documented evidence of a history (e.g. liver testing) of drug/alcohol abuse within the 12 months prior to enrollment for clinical investigation entry
- Subject is excluded if they have received an investigational therapy or approved therapy for investigational use within 30 days of surgery
- Subject is excluded if planning to participate in another research study during the follow-up phase of this study or 84 days after study completion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: WoundWand™ Debridement Device
Group I - Coblator IQTM Controller plus WoundWandTM Debridement Device.
Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound.
|
Group I - Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound
|
Active Comparator: Standard of Care sharp debridement
Group II - Standard of Care (SoC) surgical (sharp) debridement.
Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound.
|
Group II - Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bacterial Diversity and Number of Bacteria Present in the Wound
Time Frame: Day 1 (immediately pre- and post-debridement) and 4 weeks post-debridement
|
Primary endpoint was to determine bacterial diversity and number of bacteria present in the study wound at 4 weeks post- debridement using either WoundWand Debridement Device or Standard of Care. Punch biopsies were performed per standard practice to quantify the type and amount of bacteria present in wounds debrided with either Standard of Care Sharp Debridement or WoundWand Debridement Device. Debridement of contaminated tissue is essential to prevent wound infection, promote healing, and provide a neat wound edge for the prevention of scaring. A 3-4 mm punch biopsy for quantitative tissue culture (i.e. bacterial content) will be collected from the study wound site immediately pre- and post-debridement and at Week 4. The punch biopsy will be performed per standard practice and if required, utilizing the appropriate analgesia [e.g. general, local (e.g. 1% lidocaine with epinephrine)]. Quantitative tissue culture will be completed according to the laboratory's standard procedures |
Day 1 (immediately pre- and post-debridement) and 4 weeks post-debridement
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Photograph Area Measurements to Determine Reduction in Wound Size
Time Frame: Visit 2 through Visit 8 (12 weeks)
|
a) Reduction in wound size for up to 12 weeks post-debridement Photographs of the wound site were taken to determine the reduction in wound size and to assess healing progression of the study wound.
Standardization of images was ensured by the Eykona® Wound Measurement System that uses small sterile 'targets' placed on the study wound to set the focus and position of the camera thus eliminating inconsistency between images acquisition time points.
The photographs are stored on a USB (Universal Serial Bus) flash drive which will be archived with the study files.
|
Visit 2 through Visit 8 (12 weeks)
|
Wound Status Using Bates-Jensen Wound Assessment - Total Score
Time Frame: Screening through Visit 8 (12 weeks)
|
The Bates-Jensen Wound Assessment Tool is a 13-item questionnaire (size, depth, edges, undermining, necrotic tissue type, exudate type, exudate amount, skin color surrounding wound, peripheral tissue edema, peripheral tissue induration, granulation tissue, epithelialization) used to assess wound status. Total score is determined by adding together the sub-scores from each of the 13 items, with a higher score indicating a more severe wound status. Each of the 13 item scores ranged from 1 to 5 possible points. Minimum score of 13 indicated the best outcome, maximum score of 65 indicated the worst outcome. |
Screening through Visit 8 (12 weeks)
|
Braden Scale for Predicting Pressure Sore Risk - Total Score
Time Frame: Screening through Visit 8 (12 weeks)
|
The Braden Scale, performed by the Investigator (or designee), is a 6-item questionnaire (sensory perception, moisture, activity, mobility, nutrition, and friction &shear) used to assess the subject's level of risk for development of pressure ulcers. Total score is determined by adding together the sub-scores from each of the 6 items, with a lower score indicating a higher risk for developing pressure ulcers. Braden Scale thresholds: 19-23 = not at risk 15-18 = preventative interventions 13-14 = moderate risk 10-12 = high risk 6-9 = very high risk Sub-score ranges: Sensory perception: 1 - 4 Moisture: 1 - 4 Activity: 1 - 4 Mobility: 1 - 4 Nutrition: 1 - 4 Friction & Shear: 1 - 3 Total score minimum of 6 indicated a very high risk outcome, maximum score of 23 indicated the subject not at risk. |
Screening through Visit 8 (12 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Luc Teot, M.D. Phd., Hôpital Lapeyronie
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- skin
- prevention
- infection
- wound healing
- chronic wound
- diabetic foot ulcer
- wound
- debridement
- cellular senescence
- post-debridement
- wound tissue
- wound management
- WoundWand
- wound size reduction
- wound bed debridement
- WoundWand Debridement Device
- delayed healing
- acute wound
- venous leg ulcers
- radiofrequency debridement
- necrotic tissue
Additional Relevant MeSH Terms
Other Study ID Numbers
- WW-2013-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lower Leg Wound
-
3MWithdrawnLower Extremity Diabetic Leg Wounds | Lower Extremity Venous Leg Wounds | Lower Extremity Mixed Aetiology Leg WoundsUnited Kingdom
-
B. Braun Medical Inc.TerminatedWound of Lower Leg (Physical Finding)United States
-
Brigham and Women's HospitalWithdrawnWound of Knee | Wound of Skin | Non-melanoma Skin Cancer | Skin Graft Complications | Wound of Lower LegUnited States
-
Hacettepe UniversityCompletedBurn Scar | Burns | Lower Limb Injury | Lower Limb WoundTurkey
-
MediWound LtdCompletedVenous Leg Ulcers | Hard to Heal Wounds | Diabetic Lower Extremity Ulcers | Traumatic/ Post Operative WoundsIsrael
-
University Hospital, IoanninaRecruitingAnesthesia, Local | Lower Limb Wound | Upper Limb WoundGreece
-
St. Luke's-Roosevelt Hospital CenterKinetic Concepts, Inc.CompletedVenous Stasis Ulcers | Lower Extremity Wound InfectedUnited States
-
SerenaGroup, Inc.Sanara MedTechActive, not recruiting
-
University Hospital, MontpellierSociété Française de Médecine Vasculaire (SFMV)CompletedPeripheral Arterial Disease | Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)France
-
Oslo Metropolitan UniversitySophies Minde Foundation; UniCare Bakke ASCompleted
Clinical Trials on WoundWand™ Debridement Device
-
Medaxis, LLCNAMSARecruitingDiabetic Foot Ulcer | Venous Leg Ulcer | Surgical Wound Dehiscence | Traumatic WoundsUnited States
-
Hospital for Special Surgery, New YorkTerminated
-
University of SienaNot yet recruitingPeriodontitis, AdultItaly
-
School of Health Sciences GenevaCompletedWound Heal | Chronic WoundSwitzerland
-
Assistance Publique - Hôpitaux de ParisUnknown
-
Calvary Hospital, Bronx, NYCompleted
-
Medtronic Neurovascular Clinical AffairsCompletedIntracranial AneurysmUnited States, Canada
-
Medtronic Neurovascular Clinical AffairsRecruitingIntracranial Aneurysm | Ruptured AneurysmUnited States
-
Smart Medical Systems Ltd.CompletedIntestinal DiseasesUnited Kingdom
-
Medtronic Neurovascular Clinical AffairsCompletedIschemic StrokeUnited States